Table 2.
Association between FIASMA psychotropic medication use at baseline and risk of intubation or death among patients with psychiatric disorders hospitalized for severe COVID-19.
| Number of events / Number of patients | Crude Cox regression analysis | Multivariable Cox regression analysisa | Analysis weighted by inverse- probability- weighting weightsa | Number of events / Number of patients in the matched groups | Univariate Cox regression in a 1:1 ratio matched analytic sample | Cox regression in a 1:1 ratio matched analytic sample adjusted for unbalanced covariatesb | |
|---|---|---|---|---|---|---|---|
| N (%) | HR (95% CI; p-value) | HR (95% CI; p-value) | HR (95% CI; p-value) | N (%) | HR (95% CI; p-value) | HR (95% CI; p-value) | |
| No FIASMA psychotropic medication | 215 / 381 (56.4%) | Ref. | Ref. | Ref. | 77 / 164 (47%) | Ref. | Ref. |
| Any FIASMA psychotropic medication | 57 / 164 (34.8%) | 0.42 (0.31–0.57; <0.001*) | 0.49 (0.36–0.67; <0.001*) | 0.50 (0.37–0.67; <0.001*) | 57 / 164 (34.8%) | 0.65 (0.45–0.93; 0.019*) | 0.55 (0.39–0.77; 0.001*) |
aAdjusted for age, sex, hospital, obesity, and number of medical conditions.
bAdjusted for sex and obesity.
*Two-sided p-value is significant (p < 0.05).
HR hazard ratio, CI confidence interval.
Non-FIASMA psychotropic medications include medications that have either no or a relatively low in vitro FIASMA effect corresponding to an in vitro residual ASM activity lower than 50%, or for which the FIASMA effect status is unknown.